Search

Your search keyword '"Manel Pujol"' showing total 4 results
Start Over Author "Manel Pujol" Language english
4 results on '"Manel Pujol"'

1. Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period

Author

Jesús Tornero, Alba Erra, Santos Castañeda, Carolina Pérez-García, Raimon Sanmartí, Sara Marsal, Ingrid Moller, Esperanza Naredo, Miguel A González-Gay, Celia Erausquin, Ivan Castellví, Javier Llorca, Alejandro Muñoz, María Galindo, Enrique Raya, Lydia Abasolo, Gema Bonilla, Alfonso Corrales, Inmaculada Ureña, Carlos Rodríguez-Lozano, Carlos González-Juanatey, Cristina Fernandez Carballido, Francisco J López-Longo, Miguel Ángel González-Gay, Eduardo Collantes, José A Miranda-Filloy, Sagrario Bustabad, Indalecio Monteagudo, Jose A Piqueras, Tatiana Cobo, Joan Maymó, Carmen Barbadillo, Soledad Ojeda, Jaime Calvo Alen, Antonio Fernandez Nebro, Isabel Rodríguez, Pilar Font, Martina Steiner, Eugenio Chamizo Carmona, Beatriz González Álvarez, Santiago Munoz, Joan M Nolla, Fernando Sánchez-Alonso, Julio Sanchez, Raul Menor Almagro, Ana Pérez Gómez, Monica Ibañez, Elena Heras-Recuero, Trinidad Pérez Sandoval, Miren Uriarte-Ecenarro, Angela Pecondón, Hye Sang Park, Jessica Polo y La Borda, Zulema Plaza, Carmen García Gómez, Ivan Ferraz-Amaro, Jesús Tomás Sanchez-Costa, Olga Carmen Sánchez-González, Ana Isabel Turrión-Nieves, Ana Perez-Alcalá, José L FernándezSueiro, José A Pinto-Tasende, Eugenia Gonzálezde Rábago, María J González-Fernández, Ramón Huguet Codina, Beatriz Yoldi, Mercedes Ramentol, Gabriela Ávila, Cayetano Alegre, Fernando Gamero, José García Torón, María P Moreno-Gil, Antonio Juan-Mas, Pilar Espiño, Inmaculada Ros, Horacio Berman, Oscar Fontseré Patón, Benjamín Fernández Gutiérrez, José M Pina-Salvador, María D Fábregas, Montserrat Romera, Jesús A García-Vadillo, Rosario García de Vicuña, María A Belmonte, María V Irigoyen, Olga Martínez González, Rebeca Belmonte Gómez, Pastora Granados Bautista, Azucena Hernández Sanz, José Santos Rey, Carmen O Sánchez-González, Javier Bachiller, Antonio Zea, Francisco J Manero, Chesús Beltrán Audera, Marta Medrano, Jesús Babío Herráez, Javier del Pino, Ruth López González, María Enriqueta Peiró, José M Senabre, José C Rosas, Isabel Rotés, Estefanía Moreno, Javier Calvo, Amalia Rueda, Pilar Morales, Ana Nieto, Ana Ruibal Escribano, Sergio Ros Expósito, Ginés Sánchez Nievas, Enrique Júdez Navarro, Manuela Sianes Fernández, Silvia Martínez Pardo, Manel Pujol, Alberto Cantabrana, Esmeralda Delgado, Sergio Rodríguez Montero, Javier Rivera Redondo, Teresa González Hernández, Francisco J González-Polo, José M Moreno, Emilio Giner Serret, Laura Cebrián Méndez, María Teresa Navío, Teresa Pedraz Penalva, Encarnación Pagán, Pablo Mesadel Castillo, Ana Cruz, Ana Turrión, Desireé Ruíz, Antonio López Meseguer, Manuel J Moreno, Luis F Linares, Mercedes Morcillo, María L González-Gómez, José M Aramburu, Natalia A Rivera, Olaia Fernández Berrizbeitia, Manel Riera, Yolanda María León, Miriam Amirall, Jordi Fiter, Julia Fernández Melón, Luis Espadaler, Joaquín Belzunegui, Inmaculada Bañegil, César Díaz, Ramón Valls, María Bonet, Eva Revuelta Evrard, Javier R Godo, and José A González-Fernández

Subjects
Medicine
Abstract

Objective To assess the predictive value of four cardiovascular (CV) risk algorithms for identifying high-risk psoriatic arthritis (PsA) patients.Methods Evaluation of patients with PsA enrolled in the Spanish prospective project CARdiovascular in RheuMAtology. Baseline data of 669 PsA patients with no history of CV events at the baseline visit, who were followed in rheumatology outpatient clinics at tertiary centres for 7.5 years, were retrospectively analysed to test the performance of the Systematic Coronary Risk Assessment (SCORE), the modified version (mSCORE) European Alliance of Rheumatology Associations (EULAR) 2015/2016, the SCORE2 algorithm (the updated and improved version of SCORE) and the QRESEARCH risk estimator version 3 (QRISK3).Results Over 4790 years of follow-up, there were 34 CV events, resulting in a linearised rate of 7.10 per 1000 person-years (95% CI 4.92 to 9.92). The four CV risk scales showed strong correlations and all showed significant associations with CV events (p

Published
2024
Full Text
View/download PDF

2. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

Author

Cristina Valero-Martínez, Judit Font Urgelles, Meritxell Sallés, Beatriz E. Joven-Ibáñez, Alexia de Juanes, Julio Ramírez, Xavier Juanola, Raquel Almodóvar, Ana Laiz, Mireia Moreno, Manel Pujol, Emma Beltrán, José Antonio Pinto-Tasende, Laura Crespí, Luis Sala-Icardo, Santos Castañeda, and Rosario García-Vicuña

Subjects
biologics, spondyloarthritis, combination (combined) therapy, psoriatic arthritis (PsA), inflammatory bowel disease, safety, Immunologic diseases. Allergy, RC581-607
Abstract

Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. This is a retrospective, real-world multicenter study in refractory SpA and PsA patients with simultaneous use of two biological or synthetic targeted agents. Effectiveness was assessed using Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Disease Activity in Psoriatic Arthritis (DAPSA) Score. We identified 39 different DTT combinations in 36 patients (22 SpA; 14 PsA), 25 of them with concomitant inflammatory bowel disease. The most commonly used combinations were TNF inhibitor plus antagonist of the IL12/23 pathway, followed by TNF inhibitor plus IL-17 antagonist. During a median exposure of 14.86 months (IQR 8-20.2), DTT retention rate was 69.4% (n=25/36; 19 SpA, 6 PsA). Major clinical improvement (change in ASDAS-CRP > 2 or improvement > 85% in DAPSA) was achieved in 69.4% of patients (n=25/36 therapeutical combinations; 17/21 SpA, 8/15 PsA), with a 58.3% (n=21/36 combinations; 15/20 SpA, 6/13 PsA) low-activity/remission rate. Of the patients who were receiving glucocorticoids, 55% managed to withdraw them during follow-up. Interestingly, only four serious adverse events in three patients were observed, leading to DTT discontinuation.

Published
2023
Full Text
View/download PDF

3. Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain

Author

Gratacós, Jordi, Luelmo, Jesús, Rodríguez, Jesús, Notario, Jaume, Marco, Teresa Navío, de la Cueva, Pablo, Busquets, Manel Pujol, Font, Mercè García, Joven, Beatriz, Rivera, Raquel, Vega, Jose Luis Alvarez, Álvarez, Antonio Javier Chaves, Parera, Ricardo Sánchez, Carrascosa, Jose Carlos Ruiz, Martínez, Fernando José Rodríguez, Sánchez, José Pardo, Olmos, Carlos Feced, Pujol, Conrad, Galindez, Eva, Barrio, Silvia Pérez, Arana, Ana Urruticoechea, Hergueta, Mercedes, Coto, Pablo, and Queiro, Rubén

Published
2018
Full Text
View/download PDF

4. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

Author

Gomez-Reino, Juan J., Carmona, Loreto, Erra, Alba, Marsal, Sara, Castro, Mónica Fernández, Mulero, Juan, Andreu, Jose Luis, Gómez, Manuel Rodríguez, Padro, Marta Larrosa, Casado, Enrique, Leonor, Elena, Alierta, Sirvent, Reina, Delia, Gómez, Carmen García, Ibañez, Beatriz Joven, Delgado, Patricia Carreira, Hernández, Ma. Victoria, Loza, Estibaliz, Ruiz, Alberto Alonso, Itzazelaia, Esther Uriarte, Zarza, Lucia Pantoja, Aransay, Ma. Valvanera Pinillos, Hernández, Teresa Mariné, de Vicuña Pinedo, Rosario García, García, Ana Ma. Ortiz, Álvaro, Isidoro González, Laffon, Armando, Álvaro-Gracia, Jose Ma., López, César Díaz, de La Serna, Arturo Rodríguez, Cortina, Eduardo Loza, Oyarzabal, Ma. Victoria Irigoyen, Garnica, Inmaculada Ureña, Cagigal, Virginia Coret, Casasempere, Paloma Vela, Pascual, Eliseo, Serrano, Miquel Ángel Belmonte, Fabregat, Juan Beltran, Lerma, Juan José, Graña, Myriam Liz, Gómez-Reino, Juan José, Aizen, Saul Mario Gelman, Monge, Elena Ciruelo, Muriel, Eva Tomero, García, Juan Carlos Cobeta, Cuenca, Encarnación Saiz, Muñoz, José Galvez, de La Torre, Gerardo Iglesias, Pardo, Rosa Roselló, Galeano, Carlos Vázquez, de Diego, Juan Pablo Valdazo, Marsá, Xavier Tena, Santamaría, Vera Ortiz, Prada, Manuel Fernández, Piqueras, José Antonio, Tornero, Jesús, Méndez, Laura Cebrián, Carreño, Luis, Borras, Juan José García, Ruiz, Francisco Javier Manero, Busquets, Manel Pujol, Duran, Josep Granados, Cuadra, Jose Luis, Tevar, F. Javier Paulino, Huertas, Marcos Paulino, Maiz, Olga, Barastay, Estibaliz, Figueroa, Manuel, Torres, Carmen, Coro, Montserrat Corteguera, Lozano, Carlos Rodríguez, Hernández, Félix Francisco, Fernández, Iñigo Rua Figueroa, Martín, Oscar Illera, Zea Mendoza, Antonio C., de La Peña Lefebvre, Paloma García, Expósito, Marta Valero, Aznar, Emilia, Gutiérrez, Ricardo, Valenciano, Ana Cruz, Echeverria, Manuel Crespo, Del Pozo, Félix Cabero, Jimeno, Ma. Teresa Ruiz, Aresté, Jordi Fiter, Poch, Luis Espadaler, Carasa, Juan Carlos Vesga, Quintana, Eduardo Cuende, Andrada, Sagrario Sánchez, Valverde, Vicente Rodríguez, Amaro, Ivan Ferraz, García, Tomas González, Marenco, José Luis, Rejón, Eduardo, Estevez, Eduardo Collantes, Castro Villegas, M. Carmen, Hernández, Blanca, de Oca Mercader, José V. Montes, Sarabia, Federico Navarro, de Miera, Francisco Javier Toyos Saenz, Fernández-Cid, Carlos Marras, Ferran, Luis Francisco Linares, Morales, Juan Moreno, González-Montagut, Carmen, Aparicio, Ángel García, Cáliz, Rafael Cáliz, Tenorio, Carmen Idalgo, Fernández, Amalia Sánchez-Andrade, Cobo, Tatiana, Hernández, Azucena, Martín-Mola, Emilio, Fava, Xavier Arasa, Noguera Pons, José Raúl, Blasco, Francisco J. Navarro, Beltran, Juan Víctor Tovar, Gómez de Salazar, José Carlos Rosas, Soler, Gregorio Santos, Díaz, Isabel Ibero, Casado, Vega Jovani, Domenech, Raquel Martín, Barnusell, Jordi del Blanco, Hernández, Miguel Ángel Abad, Andrés, Maria Torresano, Lidon, Gaspar Pérez, Martín, Manuel Tenorio, Bañegil, Inmaculada, Guarch, Joan Maymo, García, Carolina Pérez, Carbonell, Jordi, Quevedo Vila, Víctor Eliseo, Redondo, Javier Rivera, Hernández, Teresa González, Heredia, José Manuel Rodríguez, Cid, Ángel Gallegos, Muñoz, Jesús García Arroba, Moreira, Miguel Cantalejo, Almodovar, Raquel, Donate, Javier Quiros, Montejo, Pedro Zarco, Mazzucchelli, Ramón, Martínez, Alfonso Corrales, Estruch, Dolors Boquet, Torres, Francisco Pérez, Cortes, José Ivorra, Armangue, Xavier Suris, Sandoval, Trinidad Pérez, Catalá, Javier Calvo, Campos, Cristina, Pérez, Maria Francisca Pina, Calleja, Cristina Hidalgo, Consuegra, Julia García, Muñoz, Rosa Merino, Gómez, Miquel Sala, Centellas, Montserrat, Martín, José Miguel Ruiz, Mas, Antonio Juan, Vilamajó, Inmaculada Ros, Campillo, Jaime Fernández, Molina, Rocío González, Minguez Vega, Mauricio, Tendero, Gaspar Panadero, Ruan, Jesús Ibáñez, Cristobal, Anna Martínez, Trenor, Pilar, Gil, Jenaro Graña, Peralta, Ma. Teresa Bosque, Arana, Ana Urruticoechea, Ivorra, José Román, Chalmeta, Inmaculada, López, Javier Alegre, Lario, Bonifacio Álvarez, Valdivielso, José Luis Alonso, Melón, Julia Fernández, López, Ma. Angeles Belmonte, and Montero, Dolores

Subjects
Adult, Male, Time Factors, Antibodies, Monoclonal, Humanized, Receptors, Tumor Necrosis Factor, Etanercept, Arthritis, Rheumatoid, Actuarial Analysis, Risk Factors, Humans, Spondylitis, Ankylosing, Registries, Treatment Failure, Aged, Proportional Hazards Models, Tumor Necrosis Factor-alpha, Arthritis, Arthritis, Psoriatic, Adalimumab, Antibodies, Monoclonal, Middle Aged, Infliximab, Immunoglobulin G, Chronic Disease, Retreatment, Female, Research Article
Abstract

The objective of this work is to analyze the survival of infliximab, etanercept and adalimumab in patients who have switched among tumor necrosis factor (TNF) antagonists for the treatment of chronic arthritis. BIOBADASER is a national registry of patients with different forms of chronic arthritis who are treated with biologics. Using this registry, we have analyzed patient switching of TNF antagonists. The cumulative discontinuation rate was calculated using the actuarial method. The log-rank test was used to compare survival curves, and Cox regression models were used to assess independent factors associated with discontinuing medication. Between February 2000 and September 2004, 4,706 patients were registered in BIOBADASER, of whom 68% had rheumatoid arthritis, 11% ankylosing spondylitis, 10% psoriatic arthritis, and 11% other forms of chronic arthritis. One- and two-year drug survival rates of the TNF antagonist were 0.83 and 0.75, respectively. There were 488 patients treated with more than one TNF antagonist. In this situation, survival of the second TNF antagonist decreased to 0.68 and 0.60 at 1 and 2 years, respectively. Survival was better in patients replacing the first TNF antagonist because of adverse events (hazard ratio (HR) for discontinuation 0.55 (95% confidence interval (CI), 0.34-0.84)), and worse in patients older than 60 years (HR 1.10 (95% CI 0.97-2.49)) or who were treated with infliximab (HR 3.22 (95% CI 2.13-4.87)). In summary, in patients who require continuous therapy and have failed to respond to a TNF antagonist, replacement with a different TNF antagonist may be of use under certain situations. This issue will deserve continuous reassessment with the arrival of new medications. © 2006 Gomez-Reino and Loreto Carmona; licensee BioMed Central Ltd.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results